ARCA Biopharma, Inc. ABIO Cash Flow

Arca biopharma, inc. (ABIO)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
-5,138	-5,482	-5,745	-6,182	-6,862	-7,933	-10,641	-13,481	-16,887	-18,490	-18,537	-18,763	-17,135	-16,444	-15,368	-13,523	-12,348	-11,445	-10,888	-10,358	-10,044	-9,689	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
16	18	21	22	21	22	23	24	26	27	28	29	26	24	22	19	20	19	18	16	13	12	0	0	0
Amortization of right-of-use asset - operating
77	71	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of other assets
-	-	-	-	-	-	-	-	-	329	358	358	329	296	263	228	215	189	0	0	0	-	-	-	-
Amortization of premiums and discounts on marketable securities
-	-	-	-	-	-2	-12	-30	-66	-119	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Share-based compensation
117	151	182	211	226	273	334	395	454	458	310	458	522	576	750	632	624	599	610	622	619	647	0	0	0
Change in operating assets and liabilities:
Other current assets
-321	-401	-426	-367	-407	-689	-773	-818	-798	-437	-237	-318	-156	47	32	136	-75	-213	-229	-255	-326	-214	0	0	0
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	432	0	0	0	-	-	-	-	-	-	-	-
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accounts payable
-103	188	-82	-188	-380	-392	-1,017	-659	-363	-583	222	309	227	841	384	158	93	-431	263	-128	99	198	0	0	0
Accrued compensation and employee benefits
-17	-21	-26	-20	-33	-607	-9	-7	-2	38	31	41	89	50	48	-102	29	340	15	61	12	-130	0	0	0
Accrued expenses and other liabilities
-194	-127	189	83	-134	-298	-632	-765	-530	193	196	293	556	-3	358	547	207	196	119	-12	-108	-182	0	0	0
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	0	0	0	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-15,448	-14,987	-13,765	-12,431	-11,304	-10,534	-9,793	-9,468	-8,832	-9,406	0	0	0
Net cash used in operating activities
-4,921	-4,801	-4,986	-5,675	-6,739	-8,244	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Purchases of property and equipment
0	-	-	-	-	4	0	0	0	-	-	-	-	12	10	6	10	11	0	0	0	-	-	-	-
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	5,471	5,081	16,845	20,504	0	0	0	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
-	-	-	-	-	3,050	7,800	10,300	16,900	18,400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
0	-	-	-	-	3,046	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-8,204	-16,414	-19,564	-17,018	-5,211	-11	0	0	0	-	-	-	-
Proceeds from the issuance of common stock
-	7,281	7,281	6,517	3,081	3,532	3,568	7,799	9,873	6,551	0	0	0	-	-	-	-	-	-	-	-	9,038	0	0	0
Common stock offering costs
-	372	368	287	118	117	146	344	459	448	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of principal on vendor finance agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	193	193	189	183	179	0	0	0
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	33,993	34,049	34,198	-165	8,023	0	0	0
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-23,547	-31,401	-33,387	-29,707	17,533	23,448	0	0	0	-	-	-	-
Net cash provided by financing activities
-	6,560	6,577	6,009	2,652	3,104	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase in cash and cash equivalents
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Supplemental cash flow information:
Interest paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4	4	4	3	3	0	0	0
Income tax refund received
-	167	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of noncash investing and financing transactions:
Vendor finance agreement
0	-	0	0	0	-	0	0	0	-	-	0	0	-	-	-	-	-	-	0	0	-	-	0	0
Proceeds receivable from the issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Common stock offering costs accrued but not yet paid
-	-	0	0	0	-	-	-	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Leased assets obtained in exchange for operating lease liabilities, upon adoption and extension
82	93	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in unrealized loss on marketable securities
-	-	-	-	-	2	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in unrealized loss on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-15	-19	0	0	0	-	-	-	-	-	-	-	-
Payable for purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-